16 September 2026 editorial review · Item
Baricitinib (JAK1/2 inhibitor): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: BANDIT 48-week C-peptide effect and safety abstract checked; current BARICADE registries recruit ages 1–35. Removed unsupported inexpensive/generic-style availability and inference that continuous treatment is established as necessary.
- Registry NCT07222137: RECRUITING; updated 2026-09-04; enrollment 150 (ESTIMATED); primary completion 2031-07 (ESTIMATED); results not posted in retrieved record.
- Registry NCT07222332: RECRUITING; updated 2026-09-04; enrollment 300 (ESTIMATED); primary completion 2028-07 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: NEJMoa2306691; s13063-022-06356-z; s12916-025-04201-z; 207924s006lbl.pdf; dbi20-0054.